As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.

The drug, inebilizumab, was tested in patients suffering from myasthenia gravis, which is caused by an abnormal immune ...

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...